You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,008,006


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,008,006
Title:Synthetic nucleic acid molecule compositions and methods of preparation
Abstract: A method to prepare synthetic nucleic acid molecules having reduced inappropriate or unintended transcriptional characteristics when expressed in a particular host cell.
Inventor(s): Wood; Keith V. (Mt. Horeb, WI), Wood; Monika G. (Mt. Horeb, WI), Almond; Brian (Fitchburg, WI), Paguio; Aileen (Madison, WI), Fan; Frank (Madison, WI)
Assignee: Promega Corporation (Madison, WI)
Application Number:11/825,304
Patent Claims:1. An isolated nucleic acid molecule comprising a synthetic nucleotide sequence encoding a firefly luciferase comprising a fragment of at least 300 nucleotides having 80% or less nucleic acid sequence identity to a parent nucleic acid sequence having SEQ ID NO:43 or 85% or less nucleic acid sequence identity to a parent nucleic acid sequence having SEQ ID NO:14 and having 99% or more nucleic acid sequence identity to SEQ ID NO:21, SEQ ID NO:22 or SEQ ID NO:23 or the complement thereof, wherein the decreased sequence identity is a result of different codons in the synthetic nucleotide sequence relative to the codons in the parent nucleic acid sequence, wherein the synthetic nucleotide sequence encodes a firefly luciferase which has at least 85% amino acid sequence identity to the corresponding luciferase encoded by the parent nucleic acid sequence, and wherein the synthetic nucleotide sequence has a reduced number of regulatory sequences relative to the parent nucleic acid sequence.

2. The isolated nucleic acid molecule of claim 1 wherein the regulatory sequences include transcription factor binding sequences, intron splice sites, poly(A) sites, promoter modules, and/or promoter sequences.

3. The isolated nucleic acid molecule of claim 1 wherein a majority of the codons of the synthetic nucleotide sequence which differ from the corresponding codons of the parent nucleic acid sequence are ones that are preferred codons of a desired host cell and/or are not low-usage codons in that host cell.

4. The isolated nucleic acid molecule of claim 3 wherein the majority of the codons of the synthetic nucleotide sequence which differ from the corresponding codons of the parent nucleic acid sequence are those which are employed more frequently in mammals.

5. The isolated nucleic acid molecule of claim 3 wherein the majority of the codons of the synthetic nucleotide sequence which differ from the corresponding codons of the parent nucleic acid sequence are those which are preferred codons in humans.

6. The isolated nucleic acid molecule of claim 3 wherein the majority of codons which differ are the codons CGC, CTG, AGC, ACC, CCC, GCC, GGC, GTG, ATC, AAG, AAC, GAG, CAC, GAC, TAC, TGC and TTC.

7. The isolated nucleic acid molecule of claim 1 wherein the synthetic nucleic acid molecule is expressed in a mammalian host cell at a level which is greater than that of the parent nucleic acid sequence.

8. The isolated nucleic acid molecule of claim 1 wherein the synthetic nucleic acid molecule has an increased number of AGC serine-encoding codons, an increased number of CCC proline-encoding codons, an increased number of ATC isoleucine-encoding codons and/or an increased number of ACC threonine-encoding codons relative to the number of these codons in the parent nucleic acid sequence.

9. The isolated acid molecule of claim 1 wherein the synthetic nucleotide sequence has at least 10% fewer transcription regulatory sequences relative to the parent nucleic acid sequence.

10. The isolated nucleic acid molecule of claim 1 wherein the codons in the synthetic nucleotide sequence which differ from the corresponding codons of the parent nucleic acid sequence encode the same amino acids as the corresponding codons in the parent nucleic acid sequence.

11. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid molecule encodes a fusion of the luciferase with one or more other peptides or polypeptides, wherein at least the luciferase is encoded by the synthetic nucleic acid sequence.

12. The isolated nucleic acid molecule of claim 1 wherein one or more other peptides are peptides having protein destabilization sequences.

13. A plasmid comprising the nucleic acid molecule of claim 1.

14. The plasmid of claim 13 which further comprises a multiple cloning region.

15. The plasmid of claim 13 which further comprises a promoter operatively linked to the synthetic nucleotide sequence.

16. An expression vector comprising the nucleic acid molecule of claim 1 linked to a promoter functional in a cell.

17. The expression vector of claim 16 wherein the promoter is functional in a eukaryotic cell.

18. The expression vector of claim 16 wherein the expression vector further comprises a multiple cloning site.

19. The expression vector of claim 16 wherein the promoter is functional in a mammalian cell.

20. The expression vector of claim 16 wherein the synthetic nucleotide sequence is operatively linked to a Kozak consensus sequence.

21. An isolated host cell comprising the expression cassette of claim 16.

22. An isolated host cell comprising the plasmid of claim 13.

23. A kit comprising, in suitable container means, the plasmid of claim 13.

Details for Patent 8,008,006

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2024-09-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2024-09-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2024-09-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.